Recent Updates
Recently added Catalysts

PF-06946860

Phase 1

Cachexia | Small molecule | Oncology |Pfizer, Inc.|Last Updated: Jan 12, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment11

FDA Designations

No designations recorded

Clinical trial landscape

PF-06946860 · 4 trials · 12 indications

Phase 1 4
NCT04803305Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaNon-small Cell Lung Cancer
COMPLETED18 Analytics
NCT04299048Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.Cachexia
COMPLETED11 Analytics
NCT03974776Singe Dose Study of PF- 06946860 in Healthy Adult Japanese ParticipantsHealthy
COMPLETED8 Analytics
NCT03599063Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult SubjectsHealthy
COMPLETED63 Analytics
PHASE1COMPLETED
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Non-small Cell Lung CancerUnlock trial analytics
PHASE1COMPLETED
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
CachexiaUnlock trial analytics
PHASE1COMPLETED
Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants
HealthyUnlock trial analytics
PHASE1COMPLETED
Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A
Baseline, Week 4

The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this Outcome Measure (OM), changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score at Week 4 were summarized descriptively by treatment group.

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
From Day 1 up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. An AE was considered an TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.

Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
From Day 1 up to Week 24

Participants with laboratory test abnormalities (without regard to baseline abnormality) that met pre-specified criteria included Hemoglobin\< 0.8x lower limit of normal (LLN); Hematocrit\< 0.8x LLN; Erythrocytes (Ery.)\< 0.8x LLN; Ery. Mean Corpuscular Volume\< 0.9x LLN; Leukocytes\< 0.6x LLN; Lymphocytes\< 0.8x LLN; Bilirubin\> 1.5x upper limit of normal (ULN); Aspartate Aminotransferase\> 3.0x ULN; Alkaline Phosphatase\> 3.0x ULN; Protein\< 0.8x LLN; Sodium\< 0.95x LLN; Chloride\< 0.9x LLN; Calcium\< 0.9x LLN; Bicarbonate\< 0.9x LLN; Glucose\> 1.5x ULN; C Reactive Protein\> 1.1x ULN; for urinalysis, Urine Glucose ≥1, Ketones ≥1, Urine Protein ≥1, Urine Hemoglobin ≥1, Urobilinogen ≥1, Nitrite ≥1, and Leukocyte ≥1 Esterase ≥1; Hyaline Casts \>1/LPF.

Number of Participants With Post-Baseline Vital Signs Abnormalities
From Day 1 up to Week 24

Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline ≥30 mmHg; supine diastolic blood pressure (DBP) \<50 mmHg, supine DBP increase/decrease from baseline ≥20 mmHg; supine pulse rate \<40 beats per minute (bpm) or \>120 bpm.

Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
From Day 1 up to Week 24

ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in ECG, were PR interval: value ≥300 milliseconds (msec), percentage change ≥25/50%; QRS interval: value ≥140 msec, percentage change ≥50%; QT interval: value ≥500 msec; QTcF interval: 470\< value ≤480 msec, 480\< value ≤500 msec, value \>500 msec, and 30\< change ≤60 msec, change \>60 msec.

Incidence of participants experiencing AE
Up to 20 weeks post-dose
Incidence of participants experiencing AE.
Up 9 weeks post dose

Secondary Endpoints

Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Weeks 1, 2, 3, 5 and 6 in Part A
Baseline, Weeks 1, 2, 3, 5 and 6
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Fatigue Score at Weeks 1, 2, 3, 4, 5 and 6 in Part A
Baseline, Weeks 1, 2, 3, 4, 5 and 6
Number of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part A
Day 1 through Week 6 (for a period of 6 weeks)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 TreatmentEXPERIMENTALsubcutaneous injection
Double-Blind Placebo Treatment followed by Open-Label PF-06946860 TreatmentPLACEBO_COMPARATORsubcutaneous injection
PF-06946860EXPERIMENTALsubcutaneous injection
PlaceboPLACEBO_COMPARATORSingle subcutaneous administration of placebo
Cohort 1EXPERIMENTALSingle subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
Cohort 2EXPERIMENTALSingle subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
Cohort 3EXPERIMENTALSingle subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
Cohort 4EXPERIMENTALSingle subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
Cohort 5EXPERIMENTALSingle subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
Cohort 6EXPERIMENTALSingle subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
Cohort 7EXPERIMENTALSingle subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
Optional: Cohort 8EXPERIMENTALOptional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects

Interventions

NameTypeDescription
PF-06946860DRUGsubcutaneous injection
Placebo for PF-06946860DRUGsubcutaneous injection
PlaceboOTHERPlacebo administered subcutaneously
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites33

Key Inclusion Criteria: * Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast or ovarian cancer which, in the treating oncologist's assessment, is considered advanced. * Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment Appetite...

Countries:United StatesCanada
Unlock Eligibility Criteria

Frequently asked questions about PF-06946860

What is PF-06946860 used for?

PF-06946860 is an investigational small molecule being studied for use in cachexia, anorexia, and loss of appetite in patients with advanced cancers such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, prostate cancer, breast cancer, and ovarian cancer. It has also been studied in healthy volunteers.

Who makes PF-06946860?

PF-06946860 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.

What phase is PF-06946860 in?

PF-06946860 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All four clinical trials listed for the drug are Phase 1 studies and have been completed.

What clinical trials is PF-06946860 in?

PF-06946860 has been studied in four completed Phase 1 trials. NCT03599063 and NCT03974776 tested single doses in healthy adults. NCT04299048 assessed repeated doses in patients with cancer and cachexia. NCT04803305 compared repeated doses against placebo on appetite in advanced cancer patients with anorexia.

How does PF-06946860 work?

PF-06946860 is a small molecule being investigated for its effects on appetite and body wasting in cancer patients. Its specific molecular target has not been disclosed in the available clinical trial information.